Acute kidney injury (AKI) remains a critical health problem worldwide. AKI patients requiring renal replacement therapy (dialysis) still have a 50-60% mortality rate. Patients survived dialysis-requiring AKI have a 28-fold increased risk of developing progressive chronic kidney disease (CKD), leading to end stage renal disease (ESRD). It is recognized that functioning nephrons respond to nephron deficits by increases in size and mass but not in number. Such a growth response is called compensatory nephron hypertrophy (CNH), which can occur in many situations in humans (e.g. surgical renal ablation due to renal trauma, tumor, congenital unilateral renal agenesis, or donating a kidney). Although kidney donors are highly selected from healthy individuals, recent studies have renewed our knowledge by increasingly documenting that kidney donors do have an increased risk of developing CKD and ESRD. Our goal is to define a previously undefined pathogenic role of CNH in determining the susceptibility and severity of AKI and in mediating accelerated development of interstitial fibrosis, a critical area in fighting AKI and CKD. We will also investigate the molecular mechanisms by which hypertrophied nephrons are sensitized to acute and chronic injury, with the long-term goal to identify molecular targets to reduce the incidence of AKI and development and/or progression of CKD to ESRD. Our central hypothesis is that CNH sensitizes nephrons to injury and initiates a cycle of nephron loss ? nephron hypertrophy, consequently depleting functional nephrons at an accelerated rate, ultimately leading to ESRD. Our expected outcomes include: 1) a revised understanding of the traditionally so-called ?compensatory renal hypertrophy? by demonstrating that hypertrophied nephron cells are sensitized to injury; 2) identification of the vicious cycle of nephron loss ? nephron hypertrophy as a previously under-appreciated fundamental mechanism that drives progressive nephron damage; and 3) identification of additional potential new targets for desensitizing hypertrophied nephrons from ischemic AKI. The impact of our study will include: 1) establishment of the vicious cycle of nephron loss ? nephron hypertrophy as an important mechanism underlying the progressive nature of many kidney diseases and documenting a deleterious aspect of CNH in sensitizing nephrons to injury; and 2) providing necessary preclinical knowledge about the molecular mechanisms by which CNH occurs and drives progressive nephron damage. This project may lead to development of novel and improved treatment by targeting specific signaling molecules to slow or even stop the vicious cycle of nephron loss ? nephron hypertrophy to prevent kidney disease progression.
Aim 1 will define the role of compensatory nephron hypertrophy in determining susceptibility and severity of AKI.
Aim 2 will determine the mechanisms by which compensatory nephron hypertrophy sensitizes nephrons to AKI.
Aim 3 will determine the mechanisms by which CNH accelerates development of renal fibrosis.
(PUBLIC HEALTH RELEVANCE STATEMENT) Acute kidney injury (AKI) remains a major economic and public health burden in the United States and worldwide. The studies in this proposal will determine the molecular mechanisms by which enlargement of the nephron (the structural and functional unit of the kidney) makes the nephrons sensitive to AKI and accelerated development of kidney fibrosis. The goal of this proposal is to identify potential molecular targets that may lead to development of preventive and/or therapeutic strategies to reduce the incidence and severity of AKI and thereby prevent the development and/or progression of chronic kidney disease.
|Irsik, Debra L; Chen, Jian-Kang; Brands, Michael W (2018) Chronic renal artery insulin infusion increases mean arterial pressure in male Sprague-Dawley rats. Am J Physiol Renal Physiol 314:F81-F88|
|Yang, Danyi; Livingston, Man J; Liu, Zhiwen et al. (2018) Autophagy in diabetic kidney disease: regulation, pathological role and therapeutic potential. Cell Mol Life Sci 75:669-688|
|Guo, Chunyuan; Pei, Lirong; Xiao, Xiao et al. (2017) DNA methylation protects against cisplatin-induced kidney injury by regulating specific genes, including interferon regulatory factor 8. Kidney Int 92:1194-1205|